France To Replace AstraZeneca Booster With mRNA Jab In Under-55s
The French authorities believe that the “heterologous prime-boost” approach is justified in the case of people aged under 55 years who are due to receive their second dose of the AZ COVID-19 vaccine.
You may also be interested in...
Two EU institutions have reached a deal on legislation that will give the EMA a key tool for monitoring medicines supply and preventing shortages in the event of a major public health crisis such as a future pandemic.
As more countries adopt heterologous boosting of COVID-19 vaccines in a bid to improve supplies and/or immunity while reducing side effects, vaccines expert and ex-Hilleman CEO Davinder Gill talks to Scrip in an audio interview on the challenges of the strategy and of the disease becoming endemic.
Coronavirus Notebook: New EMA Review To Contextualize Blood Clot Risk From AZ Jab, EU Gets Earlier Access To More Pfizer Vaccines
Denmark has stopped using the AstraZeneca vaccine completely, while the Canadian regulator is not recommending restrictions in any specific populations. Can a new EMA review provide better context to guide the vaccine’s use in different age groups and gender?